Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-19
2011-07-19
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S133000
Reexamination Certificate
active
07981906
ABSTRACT:
The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.
REFERENCES:
patent: 4203990 (1980-05-01), Yen et al.
patent: 4922901 (1990-05-01), Brooks et al.
patent: 4970315 (1990-11-01), Schmidhalter
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5217975 (1993-06-01), Wadsworth et al.
patent: 5219849 (1993-06-01), Lotti et al.
patent: 5276043 (1994-01-01), Lippiello et al.
patent: 5346906 (1994-09-01), Baker et al.
patent: 5510355 (1996-04-01), Bencherif et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5597919 (1997-01-01), Dull et al.
patent: 5604231 (1997-02-01), Smith et al.
patent: 5616707 (1997-04-01), Crooks et al.
patent: 5616716 (1997-04-01), Dull et al.
patent: 5663356 (1997-09-01), Ruecroft et al.
patent: 5712270 (1998-01-01), Sabb
patent: 5811442 (1998-09-01), Bencherif et al.
patent: 5824692 (1998-10-01), Lippiello et al.
patent: 5852041 (1998-12-01), Cosford et al.
patent: 5853696 (1998-12-01), Elmaleh et al.
patent: 5859004 (1999-01-01), Olesen
patent: 5861423 (1999-01-01), Caldwell et al.
patent: 5952339 (1999-09-01), Bencherif et al.
patent: 5969144 (1999-10-01), London et al.
patent: 6432975 (2002-08-01), Schmitt et al.
patent: 6734215 (2004-05-01), Shytle et al.
patent: 6953855 (2005-10-01), Mazurov et al.
patent: 7115629 (2006-10-01), Gallemi et al.
patent: 7425561 (2008-09-01), Mazurov et al.
patent: 2005/0255040 (2005-11-01), Mazurov et al.
patent: 2008/0138287 (2008-06-01), Mazurov et al.
patent: 173570 (1994-06-01), None
patent: WO 91/12254 (1991-08-01), None
patent: WO 94/08992 (1994-04-01), None
patent: WO 95/03306 (1995-02-01), None
patent: WO 96/12711 (1996-05-01), None
patent: WO 96/31475 (1996-10-01), None
patent: WO 96/40682 (1996-12-01), None
patent: WO 97/01556 (1997-01-01), None
patent: WO 97/11072 (1997-03-01), None
patent: WO 97/30998 (1997-08-01), None
patent: WO 98/25619 (1998-06-01), None
patent: WO 98/54181 (1998-12-01), None
patent: WO 99/03859 (1999-01-01), None
patent: WO 99/51602 (1999-10-01), None
patent: WO 99/62505 (1999-12-01), None
patent: WO 00/34276 (2000-06-01), None
patent: WO 01/36417 (2001-05-01), None
patent: WO 01/85727 (2001-11-01), None
patent: WO 02/15662 (2002-02-01), None
patent: WO 02/16356 (2002-02-01), None
patent: WO 02/16357 (2002-02-01), None
patent: WO 02/16358 (2002-02-01), None
patent: WO 02/17358 (2002-02-01), None
patent: WO 02/051841 (2002-07-01), None
patent: WO 2004/076449 (2004-09-01), None
Vippagunta et al, “Crystalline Solids”, Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?”, Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Arneric, S., et al., “Preclinical Pharmacology of ABT-418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease,”CNS Drug Rev.,1(1): 1-26 (1995).
Arneric, S., et al., “Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease,”Exp. Opin. Invest. Drugs,5(1): 79-100 (1996).
Astles, P.C., et al., “Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands,”Current Drug Targets—CNS&Neurological Disorders,1(4): 337-348 (2002).
Bannon, A.W., et al., “Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors,”Science,279: 77-80 (1998).
Barnes, P.J., “Nuclear Factor-kB,”Int.. J. Biochem. Cell Biol.,29(6): 867-870 (1997).
Bencherif, M., et al., “RJR-2403: A Nicotinic Agonist with CNS Selectivity I: In Vitro Characterization,”J. Pharmacol. Exper. Therapeutics,279(3): 1413-1421 (1996).
Birtwistle, J., “The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis,”Postgrad. Med. J.,72: 714-718 (1996).
CAS Printout for Begue et al., Dec. 1969.
CAS Printout for IN 173 570, Jun. 4, 1994.
CAS Printout for Schmidhalter et al., Nov. 1990.
Chiari, A., et al., “Sex Differences in Cholinergic Analgesia I: A Supplemental Nicotinic Mechanism in Normal Females,”Anesthesiology,91(5): 1447-1454 (1999).
Damaj, M.I., et al., “Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist,”J. Pharmacol. Exp. Ther.,291(1): 390-398 (1999).
Dolle, F., et al., “Synthesis and preliminary evaluation of a carbon-11-labelled agonist of the α-7 nicotinic acetylcholine receptor,”J. Labelled Comp. Radiopharm.44: 785-795 (2001).
Dunlop, J., et al., “In vitro screening strategies for nicotinic receptor ligands,”Biochemical Pharmacology,74: 1172-1181 (2007).
Ebadi, M., et al., “Neurotrophins and Their Receptors in Nerve Injury and Repair,”Neurochem Int.,30(4/5), pp. 347-374 (1997).
Ennaceur, A., et al., “A new one-trial test for neurobiological studies of memory in rats. II: effects of piracetam and pramiracetam,”Behavioural Brain Research,33: 197-207 (1989).
Evans, E.A., Isotopic labeling with carbon-14 and tritium,Principles of Radiopharmacology,11-13 (1992).
Freedman, R., et al., “Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus,”Proc. Natl. Acad. Sci.,94: 587-592 (1997).
Hanisch, U-K., et al., “Modulation of Hippocampal Acetylcholine Release: A Potent Central Action of Interleukin-2,”The Journal of Neuroscience,13(8): 3368-3374 (1993).
Heeschen, C., et al., “A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors,”J. Clin. Invest.,110(4): 527-536 (2002).
Holladay, M.W., et al., “Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery,”J. Med. Chem.,40(26): 4169-4194 (1997).
Hoyer, D. and H.W.G.M. Boddeke, “Partial agonists, full agonists, antagonists: dilemmas of definition,”TiPS Reviews,14: 270-275 (1993).
Jeyarasasingam, G., et al., “Stimulation of Non-α7 Nicotinic Receptors Partially Protects Dopaminergic Neurons from 1-Methyl-4 Phenylpyridinium-Induced Toxicity in Culture,”Neuroscience,109(2): 275-285 (2002).
Jonakait, G. M., “Neural-immune interactions in sympathetic ganglia,”TINS,16(10): 419-423 (1993).
Lavand'homme, P.M., and J.C. Eisenach, “Sex Differences in Cholinergic Analgesia II: Differing Mechanisms in Two Models of Allodynia,”Anesthesiology,91(5): 1455-1461 (1999).
Leonard, S., et al., “Nicotinic Receptor Function in Schizophrenia,”Schizophrenia Bulletin,22(3): 431-445 (1996).
Levin, E.D., and A.H. Rezvani, “Nicotinic Treatment for Cognitive Dysfunction,”Current Drug Targets: CNS and Neurological Disorders,1(4): 423-431 (2002).
Levin, E.D., et al., “AR-R17779, an α7 nicotinic agonist, improves learning and memory in rats,”Behavioural Pharmacology,10(6/7): 675-780 (1999).
Lippiello, P.M., et al., “RJR-2403: A Nicotinic Agonist with CNS Selectivity II. In Vivo Characterization,”J. P. E. T.,279(3): 1422-1429 (1996).
Macor, J.E., et al., “The 5-HT3Antagonist Tropisetron (ICS 205-930) is a Potent and Selective α7 Nicotinic Receptor Partial Agonist,”Bioorg. Med. Chem. Lett.,11: 319-321 (2001).
Madretsma, G.S., et al., “Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-α by human mononuclear cells,”Immunopharmacology,35: 47-51(1996).
Madretsma, S., et al., “In-vivo effect of nicotine on cytokine production by human non-adherent mononuclear cells,”European Journal of Gastroenterology&Hepatology,8(10): 1017-1020 (1996).
Matthys, P., et al., “Cytokines and Cachexia,”Nutrition,13(9): 763-770 (1997).
Mazurov, A., et al.,
Dull Gary Maurice
Mazurov Anatoly A.
Phillips Teresa Y.
Baek Bong-Sook
Fix Amy H.
Marschel Ardin
Targacept, Inc.
LandOfFree
(2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2662310